Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$11.31
-0.6%
$12.53
$11.25
▼
$17.31
$238.34M0.8175,981 shs81,786 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.40
-2.1%
$1.18
$0.56
▼
$2.72
$154.25M1.714.90 million shs6.49 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%-1.98%+0.53%-18.77%-30.35%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%+17.70%+44.43%+24.35%-30.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$11.31
-0.6%
$12.53
$11.25
▼
$17.31
$238.34M0.8175,981 shs81,786 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.40
-2.1%
$1.18
$0.56
▼
$2.72
$154.25M1.714.90 million shs6.49 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%-1.98%+0.53%-18.77%-30.35%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%+17.70%+44.43%+24.35%-30.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.33
Sell$13.0014.94% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$6.33352.38% Upside

Current Analyst Ratings Breakdown

Latest AMRN and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingBuy$5.00
11/11/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingSell (E+)
11/11/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingOverweight$8.00 ➝ $6.00
11/6/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingBuy$3.00 ➝ $8.00
11/3/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
DowngradeStrong-Buy ➝ Hold
11/2/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Set Price TargetNeutral ➝ Buy$5.00
11/2/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
UpgradeNeutral ➝ Buy
10/15/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Reiterated RatingSell (D-)
10/12/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
DowngradeStrong-Buy ➝ Hold
10/5/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
UpgradeHold ➝ Strong-Buy
8/21/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Initiated CoverageUnderweight$13.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$176.11M1.35$0.36 per share31.53$22.07 per share0.51
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$60K2,570.87N/AN/A$0.36 per share3.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$38.80M-$0.96N/AN/AN/A-10.87%-0.52%-0.36%N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$84.95M-$0.54N/AN/AN/AN/A-28,886.30%-75.67%N/A

Latest AMRN and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.2067-$0.50-$0.2933-$0.50$2.27 million$0.30 million
10/28/2026Q3 2026
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.0972$0.01+$0.1072$0.01$43.76 million$39.55 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.50
2.59
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
0.57
0.57

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
4.21%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
8021.07 million20.19 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
112110.18 million108.31 millionOptionable

Recent News About These Companies

Research Analysts Set Expectations for INO FY2026 Earnings
HC Wainwright Has Bearish Forecast for INO FY2026 Earnings
Inovio Pharmaceuticals' (INO) Overweight Rating Reiterated at Piper Sandler
Inovio Pharmaceuticals (NASDAQ:INO) Stock Keeps "Buy" Rating at HC Wainwright
INOVIO to Participate in Upcoming Investor Conferences
INOVIO to Participate in Upcoming Investor Conferences
Inovio (INO) Q3 2026 Earnings Call Transcript
Inovio Pharmaceuticals Q3 Earnings Call Highlights
Inovio: Q3 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$11.31 -0.07 (-0.62%)
Closing price 04:00 PM Eastern
Extended Trading
$11.31 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.40 -0.03 (-2.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.38 -0.01 (-1.07%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.